TRACK trial: Rivaroxaban fails to lower CV risks in advanced CKD

Дата публикации: 22-06-2026 13:39:34

Treatment with low-dose rivaroxaban did not reduce risks for adverse CV events and increased risks for major bleeding among patients with advanced chronic kidney disease, according to data published in JAMA.The results suggest that treatment decisions around anticoagulation may differ for patients with advanced CKD compared with other patient populations, according to Sunil V. Badve, PhD, professorial fellow at The George Institute for Global Health and the University of New South Wales in Sydney, and colleagues.“Clinical decisions regarding anticoagulation in people with advanced kidney

Классификация: Наука

Схожие новости

#	Наименование новости	Тональность	Информативность
1	Ozempic tied to improved quality of life in type 2 diabetes, CKD	0	0
2	Expanded hemodialysis noninferior to online hemodiafiltration	0	0
3	Combined creatinine-cystatin C may be comparable to measured GFR	0	0
4	At-home UACR test improves testing, follow-up rates	0	0
5	¿Necesitas tomar anticoagulantes como el Sintrom? Recuerda lo que dice el especialista	0	0
6	Pharmacy organizations, NKF ‘reenergize’ shift to race-free eGFR	0	0
7	Addressing home dialysis nurse retention, recruitment challenges	0	0
8	ЭРА антикоагулянтной терапии: настоящее, прошлое и будущее	0	0
9	Врач рассказал, насколько высок риск умереть от тромбоза глубоких вен	0	0
10	Is MAHA ready for the health challenges of rural America?	0	0

• Тональность 0
• Информативность 0
• www.healio.com